What is really different about older age bipolar disorder?

Dols, Annemiek; Sajatovic, Martha

doi:10.1016/j.euroneuro.2024.01.004

Cited by 4 publications

(1 citation statement)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It has also been described that multiple dimensions of aging seem to be altered in BD, leading to a premature aging process [3]. Older Adults with Bipolar Disorder (OABD) refers to patients older than 50 years with BD [4,5]. Approximately 25% of all patients with BD are older than 60 and this number is expected to increase to 50% in 2030 [6].…”

Section: Introductionmentioning

confidence: 99%

Facing Life in Old Age: Exploring Resilience in Older Adults with Bipolar Disorder

Montejo,

Retuerto,

Sole

et al. 2024

Preprint

View full text Add to dashboard Cite

Background: Older adults with bipolar disorder (OABD) are individuals aged 50 years and older with bipolar disorder (BD). People with BD may have fewer coping strategies or resilience. A long course of the disease, such as in OABD, could impact the development of resilience strategies, but this remains under-researched in OABD. Therefore, this study aims to assess resilience levels within the OABD and explore associated factors, hypothesizing that resilience could improve psychosocial functioning, wellbeing and quality of life of OABD patients. Methods: This study sampled 33 OABD patients from the OABD cohort at the Bipolar and Depressive Disorders Unit of Hospital Clinic of Barcelona. This was an observational, descriptive and cross-sectional study. Demographic and clinical variables as well as psychosocial functioning, resilience and cognitive reserve were analyzed. Resilience was measured using the CD-RISC-10. Non-parametric tests were used for statistical analysis. Results: The average CD-RISC-10 score was 25.67 points (SD 7.87). Resilience negatively correlated with the total number of episodes (p = 0.034), depressive episodes (p = 0.001), and the FAST (p < 0.001). Participants with normal resilience had a lower FAST (p = 0.046), a higher CRASH (p = 0.026), and more EOBD (p = 0.037) compared to those with low resilience. Conclusions: OABD individuals may exhibit lower resilience levels which correlate with more psychiatric episodes, particularly the number of depressions and worse psychosocial functioning and cognitive reserve. Better understanding and characterization of resilience could aid in early identification of patients requiring additional support to foster resilience and enhance OABD management.

show abstract

Section: Introductionmentioning

confidence: 99%

Facing Life in Old Age: Exploring Resilience in Older Adults with Bipolar Disorder

Montejo,

Retuerto,

Sole

et al. 2024

Preprint

View full text Add to dashboard Cite

show abstract

Contrasting genetic burden for bipolar disorder: Early onset versus late onset in an older adult bipolar disorder sample

Montejo,

Sole,

Fico

et al. 2025

European Neuropsychopharmacology

View full text Add to dashboard Cite

Efficacy and acceptability of lurasidone for bipolar depression: a systematic review and dose–response meta-analysis

Lin,

Chen,

Hung

et al. 2024

BMJ Ment Health

View full text Add to dashboard Cite

Question The optimal dose of lurasidone for bipolar depression is unclear. This study examined its dose–response relationship for efficacy, acceptability, and metabolic/endocrine profiles. Study selection and analysis Five databases and grey literature published until 1 August 2024, were systematically reviewed. The outcomes included efficacy (changes in depression, anxiety, clinical global impression, disability and quality of life), acceptability (dropout, manic switch, suicidality and side effects) and metabolic/endocrine profiles (changes in body weight, glucose, lipid and prolactin levels). Effect sizes were calculated using a one-step dose–response meta-analysis, expressed as standardised mean differences (SMDs), risk ratios (RRs) and mean differences (MDs) with 95% CIs. Findings Five randomised clinical trials (2032 patients, mean treatment duration 6 weeks) indicated that the optimal therapeutic dose of lurasidone (40–60 mg) improved depression (50 mg: SMD −0.60 (95% CI −0.30, –0.89)), anxiety (50 mg: −0.32 (95% CI −0.21, –0.42)), clinical global impression (50 mg: −0.67 (95% CI −0.30, –1.03)) and disability (50 mg: −0.38 (95% CI −0.08, –0.69)). Side effects increased with higher doses (50 mg: RR 1.15 (95% CI 1.05, 1.25); 100 mg: 1.18 (95% CI 1.02, 1.36)), but dropout, manic switch and suicidality did not show a dose–effect relationship. Weight increased at doses<60 mg (40 mg: MD 0.38 (95% CI 0.16, 0.60) kg), while blood glucose levels rose at doses>70 mg (100 mg: 3.16 (95% CI 0.76, 5.57) mg/dL). Prolactin levels increased in both males (50 mg: 3.21 (95% CI 1.59, 4.84) ng/mL; 100 mg: 5.61 (95% CI 2.42, 8.81)) and females (50 mg: 6.64 (95% CI 3.50, 9.78); 100 mg: 5.33 (95% CI 0.67, 10.00)). Conclusions A daily dose of 40–60 mg of lurasidone is a reasonable choice for bipolar depression treatment. Trial registration number INPLASY202430069.

show abstract

What is really different about older age bipolar disorder?

Cited by 4 publications

References 12 publications

Facing Life in Old Age: Exploring Resilience in Older Adults with Bipolar Disorder

Facing Life in Old Age: Exploring Resilience in Older Adults with Bipolar Disorder

Contrasting genetic burden for bipolar disorder: Early onset versus late onset in an older adult bipolar disorder sample

Efficacy and acceptability of lurasidone for bipolar depression: a systematic review and dose–response meta-analysis

Contact Info

Product

Resources

About